UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV)
The 5-year $59M prototype project will develop vaccines through Phase 1 trials and includes another $28.4M in additional milestones
GALVESTON, Texas & SEATTLE, November 30, 2022--(BUSINESS WIRE)--The University of Texas Medical Branch (UTMB) has been awarded a project agreement worth up to $87.4 million by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR), through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA), for the development of a vaccine technology against advanced and emerging viral threats. Two deadly viruses of significance to military personnel will be targeted for vaccine protection. These are Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129006144/en/
The project covers development of the vaccines through successful completion of Phase 1 clinical trials. UTMB has partnered with HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, to leverage the company’s self-amplifying RNA (saRNA) vaccine platform technology and proprietary LION™ delivery system to develop the vaccine candidates, identified as HDT-321 for CCHFV and HDT-331 for NiV.
HDT Bio will be allocated $49 million as a sub-performer for development of the NiV and CCHFV vaccine candidates.
"We are grateful to DOD and HHS for their support," said HDT Bio CEO Steve Reed. "We look forward to working with our partners and the MCDC to protect our military personnel and the American people as a whole from biological threats."
CCHFV is found in Europe, Africa, the Middle East and Asia and death rates range from 9% to as high as 50%. NiV outbreaks occur mostly in Asia with death occurring 61% of the time. There are no approved vaccines for these two potentially lethal viruses.
UTMB will lead the project (PI: Dr. Thomas Geisbert and Dr. Robert Cross) and work with HDT Bio (PI: Dr. Jesse Erasmus) on selection of the NiV saRNA vaccine candidates and assay development. Rocky Mountain Labs, Laboratory of Virology (PI: Dr. Heinz Feldmann), a National Institute of Allergy and Infectious Disease laboratory in Hamilton, MT, will collaborate on the selection of CCHFV saRNA vaccine candidates.
"The CoVID-19 pandemic has clearly demonstrated a shift in vaccination approaches, where RNA-based vaccines were instrumental in rapidly addressing the global need for a vaccine," said UTMB Co-PI Dr. Robert Cross, "This partnership will build on the successes of HDT Bio to generate potent RNA vaccination technologies targeting SARS-CoV-2 in order to address other high priority viruses with pandemic potential."
"The SARS-CoV-2 pandemic is an example of how quickly viruses can emerge and spread," said UTMB Co-PI Dr. Thomas Geisbert. "An important mission of the Galveston National Laboratory is to develop medical countermeasures to combat highly lethal pathogens. We thank DOD and HHS for the opportunity to work with the MCDC and our colleagues at HDT Bio and Rocky Mountain Laboratories to develop vaccines that can protect against CCHF and NiV."
CCHFV and NiV are zoonotic viruses but also can be transmitted from infected people through close contact with bodily fluids. CCHFV is transmitted by ticks with a variety of domestic and wild animals, such as cattle, sheep, goats and rabbits, serving as amplifying hosts for the virus. The virus can cause severe internal bleeding followed by organ failure and death. NiV is passed to humans from pigs and fruit bats. The virus causes encephalitis and severe respiratory disease, and outbreaks occur regularly in regions of Asia and India. NiV also poses a potential national security threat to the United States.
Both of the viruses contain multiple antigen targets that have previously been associated with protective immunity, which affords an opportunity to design and develop vaccines against more than one vulnerability using a multi-antigen approach.
"Next-generation technologies are urgently needed to enable multi-antigen RNA vaccine strategies to combat emerging infectious diseases in a safe and tolerable manner," said HDT Bio’s PI Dr. Jesse Erasmus, "With the recent emergency use authorization of our LION/saRNA platform for COVID-19, the first saRNA technology to reach this milestone, we are poised to unlock this modality’s dose-sparing capacity to achieve multi-target protective immunity in humans."
The University of Texas Medical Branch at Galveston (UTMB) is among the eight academic institutions and five health institutions of The University of Texas System (UT System). It is home to the only national laboratory in Texas, and one of only two in the nation dedicated to combatting infectious threats to health. The Galveston National Laboratory (GNL) is a National Institutes of Health (NIH)-funded biocontainment facility that was dedicated on the UTMB campus in November 2008. The laboratory serves as a national resource in support of NIH’s biodefense and emerging infectious diseases research agenda and stands ready to assist local, state, and national public health efforts in the event of a public health emergency.
ABOUT HDT BIO CORP
HDT Bio is a Seattle-based, clinical-stage biopharmaceutical development company. With core technology and expertise in nucleic acid formulation, the company develops products that seek to harness host-directed immune responses. HDT Bio’s work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company’s vaccine platform, repRNA/LION™, combines formulation and adjuvant ingredients to stabilize and deliver self-amplifying RNA to the immune system to stimulate responses. HDT Bio’s COVID19 vaccine is the first self-amplifying RNA vaccine to ever receive a regulatory authorization. https://www.hdt.bio
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006144/en/
Christopher M. Pirie, Ph.D.